Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth. 

Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.

Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.